Navigation Links
Bone Density Can Be Beefed Up With Twice-a-year shots

Boston - Make no bones about it – For those troubled with low bone density, now you can do something concrete about it. According to a study, Amgen Inc.'s experimental drug Denosumab taken twice a year can rejuvenate the density of bones present in the spine. //

The New England Journal of Medicine has reported the effect of this drug after two years of use and observation, which has formed part of the experimental study. 412 women volunteers who had low bone density were administerd the drug. One of the seven doses included the drug, or a placebo or the drug Fosamax, known by another name as alendronate.

It was observed that after a year of treatment, denosumab strengthened the bone density in the lumbar portion of the spine by 3.0 % to 6.7%, also marked by overall improvement in density of other bones. After 2 years of treatment, the increase was anywhere from 4.3 percent to 9.0 percent. Those who had received Fosamax also showed a 4.6 percent increase after a year’s treatment. The placebo administered on certain volunteers resulted in loss of bone density.

Michael McClung of the Providence Portland Medical Center in Portland, Oregon led the research team. He observed that, those women who got a 60 milligram injection of denosumab every six months, showed the best result. Till date, there is no record of any major side effects.

This study was initiated, sponsored and designed by Amgen.


'"/>




Page: 1

Related medicine news :

1. Raw Food Eating Leads To Low Bone Density
2. Brain Plays Vital Role In Maintaining Bone Density
3. Diabetic Type II Women Have Elevated Bone Density Mass
4. Breast Density and the Risk of Cancer
5. Hepatitis shots is promising
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has ... chances of acceptance to a residency in a United States hospital. Being accepted ... the U.S. , According to data released by the ECFMG®, every year, 50 ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon ... the signature product of her research center at Bio-Logic Aqua Research® Water Life ... and the greatest number of sufferers of blindness. “We think that Nature’s Tears® ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the ... from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related ... though activity levels decline over time. The study, presented today at the ...
(Date:7/21/2017)... ONTARIO, CANADA (PRWEB) , ... July 21, 2017 ... ... give insight into why concussion rates are on the rise, say researchers presenting ... Meeting today in Toronto, Ontario, Canada. , “The combination of evaluating the patterns ...
(Date:7/20/2017)... ... 2017 , ... ChenMed , a leading provider of value-based care for ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family ... of Ambulatory Services for the UVA Health System, brings 30 years of highly relevant ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July ... UTHR ) announced today that it will report ... opens on Thursday, July 27, 2017. ... on Thursday, July 27, 2017, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based ... today announced the completion of a $12.7 million Series A ... as well as the participation of existing investors. ... the support of New Ventures III and our current investors, ... the potential of our platform technology to transform the course ...
Breaking Medicine Technology: